## Contact

07402678683 (Home)
k.bergerhoff@gmail.com

www.linkedin.com/in/kate-bergerhoff (LinkedIn)


## Top Skills

Immunity

Interpersonal Skills

Target Identification & Validation

## Languages

Italian (Elementary)

English (Full Professional)

German (Native or Bilingual)

French (Limited Working)

## Publications

Regulatory T Cells Restrain Interleukin-2- And Blimp-1-Dependent Acquisition of Cytotoxic Function by CD4+ T Cells

ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment

TALEN-mediated genetic inactivation of the glucocorticoid receptor in cytomegalovirus-specific T cells.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.

# Kate Bergerhoff

R&D leader in Immuno-Oncology, Autoimmunity & Organoid Tech
Paris, Île-de-France, France

## Summary


Experienced immunologist with 6 years academic and a further 6 years of industry experience in the fields of cell therapy, immuno-oncology and immune regulation.


## Experience

### Okomera
Senior Director
December 2024 - Present (1 year 3 months)
Paris, Île-de-France, France

### Resilient Collective
Consultant
November 2024 - Present (1 year 4 months)

### Quell Therapeutics
4 years

Principal Scientist
June 2022 - August 2024 (2 years 3 months)
London, England, United Kingdom

Senior Scientist
September 2020 - June 2022 (1 year 10 months)
London, England, United Kingdom

### GammaDelta Therapeutics
2 years 4 months

Cell therapy and gene engineering Scientist
October 2018 - September 2020 (2 years)
London, United Kingdom

Research Scientist
June 2018 - October 2018 (5 months)

The Institute of Cancer Research
Postdoctoral Research Fellow
October 2015 - June 2018 (2 years 9 months)

UCL Cancer institute
PhD student
October 2011 - September 2015 (4 years)

BONE THERAPEUTICS S.A.
Intern
July 2010 - September 2010 (3 months)

Preparation of tissue sections and of different bone tumor cell lines and their immunohistochemical analysis. Cultivation and analysis of primary BM cells.

BioGenerix
Intern
July 2009 - September 2009 (3 months)

Method development of SDS-PAGE (Silverstain, Coomassie Stain) of monoclonal antibodies under GMP conditions for the preparation of new biosimilars. Overview of capillary zone electrophoresis, capillary gelelectrophoresis and validation processes of biosimilars.

## Education

University College London, U. of London
Doctor of Philosophy (PhD), Cancer immunotherapy · (2011 - 2015)

King's College London, U. of London
Master of Science (MS), Biomedical and molecular sciences research · (2010 - 2011)

Ruprecht-Karls-Universität Heidelberg
Bachelor of Science (BS), Molecular Biotechnology · (2007 - 2010)